UniQure N.V. (QURE)’in fiyatı nedir?

UniQure N.V. (QURE)’in fiyatı $50.67’dir

UniQure N.V. (QURE)’in piyasa değeri nedir?

UniQure N.V. (QURE)’in piyasa değeri $3.51B’dir.

UniQure N.V. (QURE) Geliri

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Yıl	Gelir	Değiştir
Sağlanan tarihler için yeterli veri yok.

Yıl

Gelir

Değiştir

Sağlanan tarihler için yeterli veri yok.

Şirket	Gelir	Gelir Farkı	Ülke
Vertex Pharmaceuticals Incorporated VRTX.US	$12.62B	-	US
Argenx SE ARGX.US	$6.02B	-	NL
Moderna, Inc. MRNA.US	$2.23B	-	US
CSL Limited CSL.AX	$15.74B	-	AU
Lonza Group AG LONN.SW	-	-	CH

Şirket

Gelir

Gelir Farkı

Ülke

Vertex Pharmaceuticals Incorporated

VRTX.US

$12.62B

Argenx SE

ARGX.US

$6.02B

Moderna, Inc.

MRNA.US

$2.23B

CSL Limited

CSL.AX

$15.74B

Lonza Group AG

LONN.SW

UniQure N.V.

QURE

Kategori